Immunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patients

BACKGROUND: Current approaches for treating metastatic malignant melanoma (MM) are not effective enough and are associated with serious adverse events. Due to its immunogenicity, melanoma is an attractive target for immunostimulating therapy. In this phase I/IIa study, local AdCD40L immunostimulator...

Descripción completa

Detalles Bibliográficos
Autores principales: Loskog, Angelica, Maleka, Aglaia, Mangsbo, Sara, Svensson, Emma, Lundberg, Christina, Nilsson, Anders, Krause, Johan, Agnarsdóttir, Margrét, Sundin, Anders, Ahlström, Håkan, Tötterman, Thomas H, Ullenhag, Gustav
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4984796/
https://www.ncbi.nlm.nih.gov/pubmed/27031851
http://dx.doi.org/10.1038/bjc.2016.42

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4984796/
https://www.ncbi.nlm.nih.gov/pubmed/27031851
http://dx.doi.org/10.1038/bjc.2016.42

Ejemplares similares